Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
37.26
+0.41 (+1.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,746,597
Open
36.85
Bid (Size)
34.85 (1)
Ask (Size)
37.50 (2)
Prev. Close
36.85
Today's Range
36.85 - 37.40
52wk Range
24.05 - 38.00
Shares Outstanding
388,132,400
Dividend Yield
2.36%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
3 Healthcare Stocks We Keep Off Our Radar
October 13, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...
Via
StockStory
Topics
Economy
Stocks
Performance
YTD
+44.5%
+44.5%
1 Month
+6.8%
+6.8%
3 Month
+0.5%
+0.5%
6 Month
+14.5%
+14.5%
1 Year
+38.3%
+38.3%
More News
Read More
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
How Do Investors Really Feel About Royalty Pharma?
September 16, 2025
Via
Benzinga
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
September 17, 2025
Via
StockStory
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
September 08, 2025
Via
StockStory
Topics
Economy
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 02, 2025
From
Zenas BioPharma
Via
GlobeNewswire
1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off
August 29, 2025
Via
StockStory
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
August 25, 2025
Via
Benzinga
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
August 25, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
1 Value Stock with Exciting Potential and 2 We Avoid
August 25, 2025
Via
StockStory
Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings
August 15, 2025
Via
Chartmill
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
August 15, 2025
Via
StockStory
Topics
Stocks
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
August 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today
August 12, 2025
Via
Benzinga
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
August 12, 2025
Via
StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
August 10, 2025
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Royalty Pharma (RPRX) Q2 Receipts Up 20%
August 06, 2025
Via
The Motley Fool
Frequently Asked Questions
Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 37.26
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 10/24/25 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 14.46B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 14B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.